Oliver Witzke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2883098/publications.pdf

Version: 2024-02-01

114 papers	3,516 citations	29 h-index	52 g-index
115	115	115	6318 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. Frontiers in Immunology, 2022, 13, 816220.	4.8	22
2	Comment on SchÃÆr et al. "Impact of COVID-19 on Public Mental Health and the Buffering Effect of a Sense of Coherence†High Level of COVID-19-Related Posttraumatic Stress in COVID-19 Survivors with Low Sense of Coherence. Psychotherapy and Psychosomatics, 2022, 91, 139-141.	8.8	6
3	Chloroquine Suppresses Effector B-Cell Functions and Has Differential Impact on Regulatory B-Cell Subsets. Frontiers in Immunology, 2022, 13, 818704.	4.8	4
4	Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clinical Infectious Diseases, 2022, 75, 690-701.	5.8	97
5	Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis. Vaccines, 2022, 10, 327.	4.4	7
6	Severe Acute Respiratory Syndrome Coronavirus 2 Cross-Reactive B and T Cell Responses in Kidney Transplant Patients. Transplantation Proceedings, 2022, 54, 1455-1464.	0.6	3
7	COVID-19 in Elderly, Immunocompromised or Diabetic Patients—From Immune Monitoring to Clinical Management in the Hospital. Viruses, 2022, 14, 746.	3.3	11
8	The Fungal Gut Microbiome Exhibits Reduced Diversity and Increased Relative Abundance of Ascomycota in Severe COVID-19 Illness and Distinct Interconnected Communities in SARS-CoV-2 Positive Patients. Frontiers in Cellular and Infection Microbiology, 2022, 12, 848650.	3.9	9
9	MO247: Exogen ATP has a Suppressive Effect on CD4+-T-Cells In Aav-Patients And Healthy Controls. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	O
10	Effect of HLA-G5 Immune Checkpoint Molecule on the Expression of ILT-2, CD27, and CD38 in Splenic B cells. Journal of Immunology Research, 2022, 2022, 1-8.	2.2	4
11	Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data. Infection, 2022, 50, 1543-1555.	4.7	3
12	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
13	Observational cohort study of neurological involvement among patients with SARS-CoV-2 infection. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199370.	3.5	26
14	COVID-19 immune signatures reveal stable antiviral TÂcell function despite declining humoral responses. Immunity, 2021, 54, 340-354.e6.	14.3	177
15	Generation of HBsAgâ€reactive T―and Bâ€cells following HBV vaccination in serological nonâ€responders under hemodialysis treatment. European Journal of Immunology, 2021, 51, 1278-1281.	2.9	4
16	von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019. Critical Care Medicine, 2021, 49, e512-e520.	0.9	56
17	The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression. Transplantation, 2021, 105, 2156-2164.	1.0	31
18	Reactivations of Latent Viral Infections Are Associated with an Increased Thr389 p70S6k Phosphorylation in Peripheral Lymphocytes of Renal Transplant Recipients. Viruses, 2021, 13, 424.	3.3	2

#	Article	IF	CITATIONS
19	SARS-CoV-2 Seroprevalence in Healthcare Workers in Germany: A Follow-Up Study. International Journal of Environmental Research and Public Health, 2021, 18, 4540.	2.6	11
20	Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). Viruses, 2021, 13, 756.	3.3	130
21	Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis. Vaccines, 2021, 9, 360.	4.4	74
22	Anti-SARS-CoV-2 T-cell Responses After mRNA Vaccination in Belatacept-treated Renal Transplant Patients. Transplantation, 2021, 105, e99-e99.	1.0	6
23	Detection of SARSâ€CoVâ€2â€specific memory B cells to delineate longâ€term COVIDâ€19 immunity. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2595-2599.	5.7	7
24	Coronavirus Disease 2019 Associated Risk Score, Behavior, and Symptom Prevalence in German Transplant Recipients. Transplantation Proceedings, 2021, 53, 1245-1248.	0.6	0
25	Characterization of follicular T helper cells and donor-specific T helper cells in renal transplant patients with de novo donor-specific HLA-antibodies. Clinical Immunology, 2021, 226, 108698.	3.2	5
26	SARS-CoV-2–reactive cellular and humoral immunity in hemodialysis population. Kidney International, 2021, 99, 1489-1490.	5.2	16
27	Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. Journal of Nephrology, 2021, 34, 1025-1037.	2.0	6
28	Correspondence on â€~SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'. Annals of the Rheumatic Diseases, 2021, 80, e162-e162.	0.9	15
29	Antiviral Active Compounds Derived from Natural Sources against Herpes Simplex Viruses. Viruses, 2021, 13, 1386.	3.3	29
30	Evidence of cell-mediated immune response in kidney transplants with a negative mRNA vaccine antibody response. Kidney International, 2021, 100, 479-480.	5.2	14
31	Orbital aspergillosis: a case report and review of the literature. BMC Ophthalmology, 2021, 21, 22.	1.4	7
32	Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)—study protocol for a randomized, controlled, interventional, open-label, multicenter trial. Trials, 2021, 22, 714.	1.6	10
33	Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age. Journal of Clinical Medicine, 2021, 10, 4606.	2.4	9
34	A Pro-Inflammatory Gut Microbiome Characterizes SARS-CoV-2 Infected Patients and a Reduction in the Connectivity of an Anti-Inflammatory Bacterial Network Associates With Severe COVID-19. Frontiers in Cellular and Infection Microbiology, 2021, 11, 747816.	3.9	51
35	HLA-G 3′ untranslated region gene variants are promising prognostic factors for BK polyomavirus replication and acute rejection after living-donor kidney transplant. Human Immunology, 2020, 81, 141-146.	2.4	10
36	Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. Cell Reports Medicine, 2020, 1, 100092.	6.5	148

#	Article	IF	CITATIONS
37	The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation. Scientific Reports, 2020, 10, 19594.	3.3	4
38	COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a++. Molecular Therapy, 2020, 28, 2691-2702.	8.2	35
39	P95â€Costimulatory molecules on CMV-specific T-cells in CMV IgG+ patients with systemic lupus erythematosus. , 2020, , .		1
40	Herpes Simplex Virus Type 2 Is More Difficult to Neutralize by Antibodies Than Herpes Simplex Virus Type 1. Vaccines, 2020, 8, 478.	4.4	6
41	Impaired Cytotoxic CD8 ⁺ T Cell Response in Elderly COVID-19 Patients. MBio, 2020, 11, .	4.1	108
42	Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity. Medical Microbiology and Immunology, 2020, 209, 657-668.	4.8	16
43	PO419AUTOANTIGEN-SPECIFIC TH17 AND TH22 INFLAME THE KIDNEY IN ANCA-VASCULITIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
44	P1617RENAL TRANSPLANT PATIENTS HARBOR NEUTROPHILS SECRETING B-CELL ACTIVATING FACTOR (BAFF) WHICH CAN BE SUPPRESSED BY MTOR INHIBITORS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
45	Doseâ€Dependent Acute Effects of Everolimus Administration on Immunological, Neuroendocrine and Psychological Parameters in Healthy Men. Clinical and Translational Science, 2020, 13, 1251-1259.	3.1	3
46	SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. Journal of Clinical Virology, 2020, 128, 104437.	3.1	307
47	Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients. Vaccine, 2020, 38, 3339-3350.	3.8	20
48	Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [18F]FDG PET/CT and [18F]FDG PET/MRI. Nuclear Medicine and Molecular Imaging, 2020, 54, 183-191.	1.0	7
49	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney International, 2020, 98, 1044-1052.	5.2	103
50	Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome. Bioscience Reports, 2020, 40, .	2.4	4
51	Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in Kidney Transplant Recipients. Vaccines, 2019, 7, 84.	4.4	9
52	HLA-E Polymorphism Determines Susceptibility to BK Virus Nephropathy after Living-Donor Kidney Transplant. Cells, 2019, 8, 847.	4.1	14
53	Successful early sofosbuvirâ€based antiviral treatment after transplantation of kidneys from HCVâ€viremic donors into HCVâ€negative recipients. Transplant Infectious Disease, 2019, 21, e13146.	1.7	26
54	Th17 cells: do regulatory B-cells (Breg) take control in ANCA-vasculitis?. Rheumatology, 2019, 58, 1329-1330.	1.9	3

#	Article	IF	CITATIONS
55	IL-22 production of effector CD4+ T-cells is altered in SLE patients. European Journal of Medical Research, 2019, 24, 24.	2.2	6
56	BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease. International Journal of Molecular Sciences, 2019, 20, 4505.	4.1	24
57	Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. New England Journal of Medicine, 2019, 381, 1136-1147.	27.0	108
58	Expression pattern of co-inhibitory molecules on CMV-specific T-cells in lung transplant patients. Clinical Immunology, 2019, 208, 108258.	3.2	1
59	Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants. BMC Nephrology, 2019, 20, 167.	1.8	3
60	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. American Journal of Transplantation, 2019, 19, 3018-3034.	4.7	97
61	An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in deÂnovo kidney transplant patients. Kidney International, 2019, 96, 231-244.	5.2	69
62	Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients. Journal of Immunology Research, 2019, 2019, 1-8.	2.2	5
63	B-cell dynamics during experimental endotoxemia in humans. Bioscience Reports, 2019, 39, .	2.4	12
64	Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients. Transplant Infectious Disease, 2019, 21, e13088.	1.7	8
65	The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation. Journal of Clinical Virology, 2019, 113, 14-19.	3.1	8
66	Evaluation of hemostasis in patients with end-stage renal disease. PLoS ONE, 2019, 14, e0212237.	2.5	43
67	Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. BMC Nephrology, 2019, 20, 430.	1.8	11
68	Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function. Transplantation Direct, 2019, 5, e419.	1.6	6
69	Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry. Journal of Visualized Experiments, 2019, , .	0.3	0
70	The Co-inhibitor BTLA Is Functional in ANCA-Associated Vasculitis and Suppresses Th17 Cells. Frontiers in Immunology, 2019, 10, 2843.	4.8	10
71	Th17 cells in renal inflammation and autoimmunity. Autoimmunity Reviews, 2019, 18, 129-136.	5.8	64
72	Learned immunosuppressive placebo responses in renal transplant patients. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4223-4227.	7.1	74

#	Article	IF	CITATIONS
73	Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. American Journal of Transplantation, 2018, 18, 1726-1734.	4.7	47
74	Susceptibility of HLA-E*01:03 Allele Carriers to Develop Cytomegalovirus Replication After Living-Donor Kidney Transplantation. Journal of Infectious Diseases, 2018, 217, 1918-1922.	4.0	18
75	IL-21 dependent Granzyme B production of B-cells is decreased in patients with lupus nephritis. Clinical Immunology, 2018, 188, 45-51.	3.2	15
76	Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival. Transplant Immunology, 2018, 47, 10-17.	1.2	10
77	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. American Journal of Transplantation, 2018, 18, 2965-2976.	4.7	11
78	Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients. Transplantation, 2018, 102, 876-882.	1.0	53
79	Impact of lowâ€level <scp>BK</scp> polyomavirus viremia on intermediateâ€term renal allograft function. Transplant Infectious Disease, 2018, 20, e12817.	1.7	17
80	Undue Elevation of Procalcitonin in Pediatric Paracetamol Intoxication is Not Explained by Liver Cell Injury Alone. Annals of Hepatology, 2018, 17, 631-637.	1.5	10
81	Are Adverse Events Induced by the Acute Administration of Calcineurin Inhibitor Cyclosporine A Behaviorally Conditioned in Healthy Male Volunteers?. Clinical Therapeutics, 2018, 40, 1868-1877.	2.5	8
82	Impact of immune suppressive agents on the BK-Polyomavirus non coding control region. Antiviral Research, 2018, 159, 68-76.	4.1	12
83	The Donor Major Histocompatibility Complex Class I Chain-Related Molecule A Allele rs2596538 G Predicts Cytomegalovirus Viremia in Kidney Transplant Recipients. Frontiers in Immunology, 2018, 9, 917.	4.8	7
84	Pro-Inflammatory Th1 and Th17 Cells Are Suppressed During Human Experimental Endotoxemia Whereas Anti-Inflammatory IL-10 Producing T-Cells Are Unaffected. Frontiers in Immunology, 2018, 9, 1133.	4.8	22
85	Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrology Dialysis Transplantation, 2018, 35, 298-303.	0.7	17
86	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2018, 29, 1979-1991.	6.1	193
87	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. BMC Nephrology, 2018, 19, 154.	1.8	3
88	T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. Journal of Clinical Virology, 2018, 105, 91-96.	3.1	35
89	Association of high HLA-E expression during acute cellular rejection and numbers of HLA class I leader peptide mismatches with reduced renal allograft survival. Immunobiology, 2017, 222, 536-543.	1.9	18
90	Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients. Transplantation, 2017, 101, 980-986.	1.0	42

#	Article	lF	Citations
91	Granzyme B producing B-cells in renal transplant patients. Clinical Immunology, 2017, 184, 48-53.	3.2	20
92	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrology Dialysis Transplantation, 2017, 32, 1060-1070.	0.7	31
93	Effects of acute systemic inflammation on the interplay between sad mood and affective cognition. Translational Psychiatry, 2017, 7, 1281.	4.8	38
94	Citrate shows protective effects on cardiovascular and renal function in ischemia-induced acute kidney injury. BMC Nephrology, 2017, 18, 130.	1.8	20
95	Increased resistance of gram-negative urinary pathogens after kidney transplantation. BMC Nephrology, 2017, 18, 164.	1.8	25
96	Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome. Kidney International Reports, 2017, 2, 53-59.	0.8	20
97	Recipient HLA-G +3142 CC Genotype and Concentrations of Soluble HLA-G Impact on Occurrence of CMV Infection after Living-Donor Kidney Transplantation. International Journal of Molecular Sciences, 2017, 18, 2338.	4.1	16
98	Characterization of injury in isolated rat proximal tubules during cold incubation and rewarming. PLoS ONE, 2017, 12, e0180553.	2.5	10
99	Renal Transplant Recipients Treated with Calcineurin-Inhibitors Lack Circulating Immature Transitional CD19+CD24hiCD38hi Regulatory B-Lymphocytes. PLoS ONE, 2016, 11, e0153170.	2.5	46
100	Prediction of renal function upon reperfusion by <i>ex situ</i> controlled oxygenated rewarming. European Journal of Clinical Investigation, 2016, 46, 1024-1030.	3.4	25
101	Morbidity and Mortality Rounds in Liver Transplantation. Visceral Medicine, 2016, 32, 272-277.	1.3	7
102	Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?. Transplantation Reviews, 2016, 30, 3-12.	2.9	21
103	Resilience and quality of life in 161 living kidney donors before nephrectomy and in the aftermath of donation: a naturalistic single center study. BMC Nephrology, 2015, 16, 164.	1.8	34
104	Neurobehavioral consequences of small molecule-drug immunosuppression. Neuropharmacology, 2015, 96, 83-93.	4.1	15
105	Phosphorylcholine antibodies are diminished in <scp>ANCA</scp> â€associated vasculitis. European Journal of Clinical Investigation, 2015, 45, 686-691.	3.4	10
106	IFN- \hat{l}^3 licenses CD11b+ cells to induce progression of systemic lupus erythematosus. Journal of Autoimmunity, 2015, 62, 11-21.	6.5	12
107	Catechol-O-Methyltransferase Val158Met Polymorphism Is Associated with Somatosensory Amplification and Nocebo Responses. PLoS ONE, 2014, 9, e107665.	2.5	43
108	Abnormal Expression Pattern of the IL-2 Receptor (i) \hat{l}^2 (i)-Chain on CD4(sup)(b)+(b)(sup)T Cells in ANCA-Associated Vasculitis. Disease Markers, 2014, 2014, 1-9.	1.3	15

#	Article	IF	CITATIONS
109	Short-term treatment with the calcineurin inhibitor cyclosporine A decreases HPA axis activity and plasma noradrenaline levels in healthy male volunteers. Pharmacology Biochemistry and Behavior, 2014, 126, 73-76.	2.9	6
110	Rituximab and B-Cell Return in ANCA-Associated Vasculitis. American Journal of Kidney Diseases, 2014, 63, 1066.	1.9	3
111	Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial. Transplantation, 2012, 93, 61-68.	1.0	138
112	New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney International, 2011, 79, 599-612.	5.2	131
113	Conversion to sirolimus of patients with chronic allograft nephropathy—a retrospective analysis of outcome and influencing factors. Langenbeck's Archives of Surgery, 2009, 394, 1073-1078.	1.9	1
114	Successful Treatment of Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab Blood, 2008, 112, 2294-2294.	1.4	1